NSABP FC‐6: Surgical conversion rate in colorectal cancer patients with unresectable, KRAS wild‐type liver metastases receiving mFOLFOX7 plus cetuximab-Reference-Cited by-同舟云学术

NSABP FC‐6: Surgical conversion rate in colorectal cancer patients with unresectable, KRAS wild‐type liver metastases receiving mFOLFOX7 plus cetuximab

Published:2022-09-16 Issue:8 Volume:126 Page:1494-1503
ISSN:0022-4790
Container-title:Journal of Surgical Oncology
language:en
Short-container-title:Journal of Surgical Oncology

Author:

Wagman Lawrence D.¹²,Geller David A.¹³,Jacobs Samuel A.⁴,Petrelli Nicholas J.¹⁵,Allegra Carmen J.¹⁶,Lipchik Corey⁷,Pogue‐Geile Katherine L.⁷,Srinivasan Ashok¹,Wang Ying⁷,O'Connell Michael J.¹,

Affiliation:

1. Department of Medicine NSABP Foundation Pittsburgh PA

2. Department of Surgery/Oncology City of Hope Orange CA

3. Department of Surgery/Oncology, UPMC Hillman Cancer Center University of Pittsburgh Pittsburgh PA

4. Department of Oncology/Hematology NSABP Foundation Pittsburgh PA

5. Department of Surgery/Oncology Christiana Care Health Service/Helen F Graham Cancer Center; Newark DE

6. Department of Medicine, Hematology/Oncology University of Florida Gainesville FL

7. Department of Pathology NSABP Foundation Pittsburgh PA

Publisher

Wiley

Subject

Oncology,General Medicine,Surgery